ABL1 TKI Resistance Mutation Detection with Interpretation
Label Mnemonic: HEMEABL, HEMEABLBM
Epic code: LAB8915 for Blood
LAB8919 for Bone Marrow
Downtime form: A-1a Doctor/Provider Orders - Pathology Molecular
Molecular Pathology
6240 RCP
384-9568
Specimen(s):
Blood or Bone Marrow Aspirate
Specimen Instructions:
Testing requires dedicated collection tube.
Collection Medium:
Pink top tube 6 mL (K2-EDTA)
Minimum:
Whole blood (EDTA anti-coagulated; 6 mL pink top tube) or bone marrow aspirate (EDTA anti-coagulated; pink or lavender top tube).
Rejection Criteria:
Serum or plasma. Specimens collected in anticoagulants other than EDTA. Frozen Specimens.
Delivery Instructions:
Store and send whole blood refrigerated. DO NOT CENTRIFUGE.
Testing Schedule:
Weekly
Turn Around Time:
21 days
Reference Range:
No variants detected.
Comments:
Testing is for detection of ABL1 tyrosine kinase domain mutations that confer resistance to TKI therapy in patients with BCR-ABL1 positive chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).

This assay is not intended to be used for detection or quantification of BCR-ABL1 fusion transcripts.

Testing is recommended for patients who exhibit treatment failure as evidenced by rising BCR-ABL1 fusion transcript levels. A BCR-ABL1 fusion transcript level of 5%IS (percent International Standard) is necessary for testing.

The limit of detection for variants is 1.0% mutant allele fraction.
Methodology:
RNA is isolated from whole blood. Reverse transcription and anchored multiplex PCR are performed for targeted next-generation sequencing (Illumina based sequencing) to detect variants in the ABL1 gene spanning amino acids 85 – 559.
CPT Code:
81170